Supplementary Tables - Clinical Cancer Research.pptx

Specimen
CTC
Tissue
Marker
Antibody
Source
Antibody
Source
ER
monoclonal murine ER-
Janssen Diagnostics, LLC
monoclonal murine, clone 1D5, 1:50, high pH epitope retrieval solution
DAKO
BCL-2
monoclonal murine monoclonal BCL-2/ (100)
BD Pharmingen
rabbit polyclonal antibody, 1:100, no antigen retrival, Envision+ detection system
DAKO
HER2
monoclonal murine Her81
Janssen Diagnostics, LLC
monoclonal murine monoclonal, Clone 124, 1:100, low pH epitope retrieval solution, LSAB+ detection system
DAKO
Ki67
monoclonal murine B56
BD Pharmingen
monoclonal murine, clone MIB-1, 1:100, high pH epitope retrieval solution, LSAB+ detection system
DAKO
Table S1. Antibodies used for CTC and tissue studies.
Group
Stop for ess
Continue to next group
Stop for failure
1
5
0 – 4
N/A
2
6 – 10
4 – 5
0 – 3
3
9 – 15
N/A
4 – 8
Table S2. Stage 2 stopping rules for the cumulative number of essfully assayed patients
Low
(Favorable)
Intermediate
High (Unfavorable)
Number of CTC/ (mean of 4 aliquots)
<5
5-10
> 10
CTC-Enumeration Points
0
1
2
Presumed Prediction of Response to ET
Favorable
Intermediate
Unfavorable
% CTC positive
Assigned Bio-Points
% CTC positive
Assigned Bio-Points
% CTC positive
Assigned Bio-Points
ER
>10%
0
1-10%b
2
0%b
6b
BCL-2
>10%
0
1-10%
1
0%
2
HER2
0%
0
1-10%
1
>10%
2
Ki67
0%
0
1-10%
1